| __timestamp | Iovance Biotherapeutics, Inc. | Lantheus Holdings, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 9335772 | 176081000 |
| Thursday, January 1, 2015 | 999000 | 157939000 |
| Friday, January 1, 2016 | 978000 | 164073000 |
| Sunday, January 1, 2017 | 952000 | 169243000 |
| Monday, January 1, 2018 | 956000 | 168489000 |
| Tuesday, January 1, 2019 | 8122999 | 172526000 |
| Wednesday, January 1, 2020 | 8712000 | 200649000 |
| Friday, January 1, 2021 | 13980000 | 237513000 |
| Saturday, January 1, 2022 | 21135000 | 353358000 |
| Sunday, January 1, 2023 | 10755000 | 586886000 |
Infusing magic into the data realm
In the ever-evolving landscape of the healthcare industry, understanding cost dynamics is crucial. Over the past decade, Lantheus Holdings, Inc. and Iovance Biotherapeutics, Inc. have showcased contrasting trends in their cost of revenue. From 2014 to 2023, Lantheus Holdings experienced a significant increase, with costs surging by over 230%, peaking in 2023. This reflects their aggressive expansion and investment in cutting-edge medical imaging solutions.
Conversely, Iovance Biotherapeutics, a pioneer in cell therapy, maintained a relatively stable cost structure, with a modest increase of around 15% over the same period. This stability highlights their strategic focus on innovation while managing operational expenses. The data underscores the diverse strategies employed by these companies in navigating the competitive healthcare market, offering valuable insights for investors and industry analysts alike.
Cost of Revenue Trends: AbbVie Inc. vs Iovance Biotherapeutics, Inc.
Analyzing Cost of Revenue: Bristol-Myers Squibb Company and Iovance Biotherapeutics, Inc.
Cost of Revenue Comparison: Teva Pharmaceutical Industries Limited vs Iovance Biotherapeutics, Inc.
Cost Insights: Breaking Down Neurocrine Biosciences, Inc. and Iovance Biotherapeutics, Inc.'s Expenses
Cost of Revenue Trends: Incyte Corporation vs Lantheus Holdings, Inc.
Analyzing Cost of Revenue: BioMarin Pharmaceutical Inc. and Lantheus Holdings, Inc.
Lantheus Holdings, Inc. vs Perrigo Company plc: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Lantheus Holdings, Inc. and Supernus Pharmaceuticals, Inc.'s Expenses
Comparing Cost of Revenue Efficiency: PTC Therapeutics, Inc. vs Iovance Biotherapeutics, Inc.
Agios Pharmaceuticals, Inc. vs Iovance Biotherapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Iovance Biotherapeutics, Inc. and Wave Life Sciences Ltd.
Cost of Revenue: Key Insights for Iovance Biotherapeutics, Inc. and Evotec SE